Abstract
Prostate-specific membrane antigen (PSMA), also called glutamate carboxypeptidase II (GCP(II)), is a Zn-dependent metalloprotease that is known as a well prostate cancer indication and a potential targeting towards anti-cancer medicines and drug delivery. Because of its centrality in the diagnostics and treatment of prostate cancer, several types of inhibitors are designed with particular scaffolds. In this study, important groups of related inhibitors as well as reported experimental and computational studies are being reviewed, in which we examined three functional groups on each group of structures. The importance of computational biochemistry and the necessity of extensive research in this area on PSMA and its effective ligands are recommended.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abdullahi M, Uzairu A, Shallangwa GA, Mamza P, Arthur DE, Ibrahim MT (2020) In-silico modelling studies on some C14-urea-tetrandrine derivatives as potent anti-cancer agents against prostate (PC3) cell line. J King Saud Univ Sci 32:770–779. https://doi.org/10.1016/j.jksus.2019.01.008
Anderson MO, Wu LY, Santiago NM, Moser JM, Rowley JA, Bolstad ES, Berkman CE (2007) Substrate specificity of prostate-specific membrane antigen. Bioorg Med Chem 15:6678–6686. https://doi.org/10.1016/j.bmc.2007.08.006
Barinka C, Byun Y, Dusich CL, Banerjee SR, Chen Y, Castanares M, Kozikowski AP, Mease RC, Pomper MG, Lubkowski J (2008b) Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J Med Chem 51:7737–7743. https://doi.org/10.1021/jm800765e
Barinka C, Hlouchova K, Rovenska M, Majer P, Dauter M, Hin N, Ko Y-S, Tsukamoto T, Slusher BS, Konvalinka J, Lubkowski J (2008b) Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs. J Mol Biol 376:1438–1450. https://doi.org/10.1016/j.jmb.2007.12.066
Barinka C, Rinnová M, Sácha P, Rojas C, Majer P, Slusher BS, Konvalinka J (2002) Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. J Neurochem 80:477–87. https://doi.org/10.1046/j.0022-3042.2001.00715.x
Bařinka C, Rojas C, Slusher B, Pomper M (2012) Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr Med Chem 19:856–870. https://doi.org/10.2174/092986712799034888
Bařinka C, Rovenská M, Mlčochová P, Hlouchová K, Plechanovová A, Majer P, Tsukamoto T, Slusher BS, Konvalinka J, Lubkowski J (2007) Structural Insight into the pharmacophore pocket of human glutamate carboxypeptidase II. J Med Chem 50:3267–3273. https://doi.org/10.1021/jm070133w
Barinka C, Sácha P, Sklenár J, Man P, Bezouska K, Slusher BS, Konvalinka J (2004) Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein Sci 13:1627–1635. https://doi.org/10.1110/ps.04622104
Baruah MM, Sharma N (2019) In silico identification of key genes and signaling pathways targeted by a panel of signature microRNAs in prostate cancer. Med Oncol 36:43. https://doi.org/10.1007/s12032-019-1268-y
Behr SC, Aggarwal R, Vanbrocklin HF, Flavell RR, Gao K, Small EJ, Blecha J, Jivan S, Hope TA, Simko JP, Kurhanewicz J, Noworolski SM, Korn NJ, de los Santos R, Cooperberg MR, Carroll PR, Nguyen HG, Greene KL, Langton-Webster B, Berkman CE, Seo Y, (2019) Phase I study of CTT1057, an (18)F-labeled imaging agent with phosphoramidate core targeting prostate-specific membrane antigen in prostate cancer. J Nucl Med 60:910–916. https://doi.org/10.2967/jnumed.118.220715
Chandran SS, Banerjee SR, Mease RC, Pomper MG, Denmeade SR (2008) Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). Cancer Biol Ther 7:974–982. https://doi.org/10.4161/cbt.7.6.5968
Chang HJ, Yoo BC, Lim SB, Jeong SY, Kim WH, Park JG (2005) Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its prognostic significance. Clin Cancer Res 11:3288–3295. https://doi.org/10.1158/1078-0432.CCR-04-1912
Chen Y, Foss CA, Byun Y, Nimmagadda S, Pullambhatla M, Fox JJ, Castanares M, Lupold SE, Babich JW, Mease RC, Pomper MG (2008) Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem 51:7933–7943. https://doi.org/10.1021/jm801055h
Choy CJ, Ling X, Geruntho JJ, Beyer SK, Latoche JD, Langton-Webster B, Anderson CJ, Berkman CE (2017) (177)Lu-labeled phosphoramidate-based PSMA inhibitors: the effect of an albumin binder on biodistribution and therapeutic efficacy in prostate tumor-bearing mice. Theranostics 7:1928–1939. https://doi.org/10.7150/thno.18719
Dannoon S, Ganguly T, Cahaya H, Geruntho JJ, Galliher MS, Beyer SK, Choy CJ, Hopkins MR, Regan M, Blecha JE, Skultetyova L, Drake CR, Jivan S, Barinka C, Jones EF, Berkman CE, Vanbrocklin HF (2016) Structure–activity relationship of 18F-labeled phosphoramidate peptidomimetic prostate-specific membrane antigen (PSMA)-targeted inhibitor analogues for PET imaging of prostate cancer. J Med Chem 59:5684–5694. https://doi.org/10.1021/acs.jmedchem.5b01850
Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ (2005) Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci 102:5981. https://doi.org/10.1073/pnas.0502101102
Eder M, Schäfer M, Bauder-Wust U, Hull WE, Wängler C, Mier W, Haberkorn U, Eisenhut M (2012) 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 23:688–97. https://doi.org/10.1021/bc200279b
Felber VB, Valentin MA, Wester H-J (2021) Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors? EJNMMI Radiophar Chem 6:10. https://doi.org/10.1186/s41181-021-00124-1
Ferraris DV, Majer P, Ni C, Slusher CE, Rais R, Wu Y, Wozniak KM, Alt J, Rojas C, Slusher BS, Tsukamoto T (2014) δ-Thiolactones as prodrugs of thiol-based glutamate carboxypeptidase II (GCPII) inhibitors. J Med Chem 57:243–247. https://doi.org/10.1021/jm401703a
Ferraris DV, Shukla K, Tsukamoto T (2012) Structure-activity relationships of glutamate carboxypeptidase II (GCPII) inhibitors. Curr Med Chem 19:1282–1294. https://doi.org/10.2174/092986712799462658
Foss CA, Mease RC, Cho SY, Kim HJ, Pomper MG (2012) GCPII imaging and cancer. Curr Med Chem 19:1346–1359. https://doi.org/10.2174/092986712799462612
Foss CA, Mease RC, Fan H, Wang Y, Ravert HT, Dannals RF, Olszewski RT, Heston WD, Kozikowski AP, Pomper MG (2005) Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res 11:4022–4028. https://doi.org/10.1158/1078-0432.CCR-04-2690
Ghadge GD, Slusher BS, Bodner A, Canto MD, Wozniak K, Thomas AG, Rojas C, Tsukamoto T, Majer P, Miller RJ, Monti AL, Roos RP (2003) Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc Natl Acad Sci U S A 100:9554–9559. https://doi.org/10.1073/pnas.1530168100
Giesel FL, Will L, Lawal I, Lengana T, Kratochwil C, Vorster M, Neels O, Reyneke F, Haberkon U, Kopka K, Sathekge M (2018) Intraindividual comparison of (18)F-PSMA-1007 and (18)F-DCFPyL PET/CT in the prospective evaluation of patients with newly diagnosed prostate carcinoma: a pilot study. J Nucl Med 59:1076–1080. https://doi.org/10.2967/jnumed.117.204669
Haas HS, Linecker A, Pfragner R, Sadjak A (2010) Peripheral glutamate signaling in head and neck areas. Head Neck 32:1554–1572. https://doi.org/10.1002/hed.21438
Hlouchová K, Bařinka C, Konvalinka J (2012) Chapter 3 Glutamate carboxypeptidase II as a therapeutic target. Proteinases as Drug Targets. Royal Soc Chem. https://doi.org/10.1039/9781849733151-00062
Huang SS, Heston WDW (2017) Should low molecular weight PSMA targeted ligands get bigger and use albumin ligands for PSMA targeting? Theranostics 7:1940–1941. https://doi.org/10.7150/thno.20284
Ivanenkov YA, Machulkin AE, Garanina AS, Skvortsov DA, Uspenskaya AA, Deyneka EV, Trofimenko AV, Beloglazkina EK, Zyk NV, Koteliansky VE, Bezrukov DS, Aladinskaya AV, Vorobyeva NS, Puchinina MM, Riabykh GK, Sofronova AA, Malyshev AS, Majouga AG (2019) Synthesis and biological evaluation of Doxorubicin-containing conjugate targeting PSMA. Bioorg Med Chem Lett 29:1246–1255. https://doi.org/10.1016/j.bmcl.2019.01.040
Jackson PF, Cole DC, Slusher BS, Stetz SL, Ross LE, Donzanti BA, Trainor DA (1996) Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase. J Med Chem 39:619–622. https://doi.org/10.1021/jm950801q
Jackson PF, Tays KL, Maclin KM, Ko Y-S, Li W, Vitharana D, Tsukamoto T, Stoermer D, Lu X-CM, Wozniak K, Slusher BS (2001) Design and pharmacological activity of phosphinic acid based NAALADase inhibitors. J Med Chem 44:4170–4175. https://doi.org/10.1021/jm0001774
Jones W, Griffiths K, Barata PC, Paller CJ (2020) PSMA theranostics: review of the current status of PSMA-targeted imaging and radioligand therapy. Cancers (Basel) 12. https://doi.org/10.3390/cancers12061367
Kalariti N, Lembessis P, Koutsilieris M (2004) Characterization of the glutametergic system in MG-63 osteoblast-like osteosarcoma cells. Anticancer Res 24:3923–3929. https://ar.iiarjournals.org/content/24/6/3923.short/. Accessed Oct 2004
Kiess AP, Banerjee SR, Mease RC, Rowe SP, Rao A, Foss CA, Chen Y, Yang X, Cho SY, Nimmagadda S, Pomper MG (2015) Prostate-specific membrane antigen as a target for cancer imaging and therapy. Q J Nucl Med Mol Imaging 59:241–268. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4859214/. Accessed July 2015
Klusák V, Bařinka C, Plechanovová A, Mlčochová P, Konvalinka J, Rulíšek L, Lubkowski J (2009) Reaction mechanism of glutamate carboxypeptidase II revealed by mutagenesis, X-ray crystallography, and computational methods. Biochemistry 48:4126–4138. https://doi.org/10.1021/bi900220s
Kopka K, Benešová M, Bařinka C, Haberkorn U, Babich J (2017) Glu-ureido-based inhibitors of prostate-specific membrane antigen: lessons learned during the development of a novel class of low-molecular-weight theranostic radiotracers. J Nucl Med 58:17s–26s. https://doi.org/10.2967/jnumed.116.186775
Kozikowski AP, Nan F, Conti P, Zhang J, Ramadan E, Bzdega T, Wroblewska B, Neale JH, Pshenichkin S, Wroblewski JT (2001) Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J Med Chem 44:298–301. https://doi.org/10.1021/jm000406m
Kozikowski AP, Zhang J, Nan F, Petukhov PA, Grajkowska E, Wroblewski JT, Yamamoto T, Bzdega T, Wroblewska B, Neale JH (2004) Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J Med Chem 47:1729–1738. https://doi.org/10.1021/jm0306226
Lapi SE, Wahnishe H, Pham D, Wu LY, Nedrow-Byers JR, Liu T, Vejdani K, Vanbrocklin HF, Berkman CE, Jones EF (2009) Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. J Nucl Med 50:2042–2048. https://doi.org/10.2967/jnumed.109.066589
Liu T, Toriyabe Y, Kazak M, Berkman CE (2008a) Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics. Biochemistry 47:12658–12660. https://doi.org/10.1021/bi801883v
Liu T, Wu LY, Hopkins MR, Choi JK, Berkman CE (2010) A targeted low molecular weight near-infrared fluorescent probe for prostate cancer. Bioorg Med Chem Lett 20:7124–7126. https://doi.org/10.1016/j.bmcl.2010.09.057
Liu T, Wu LY, Kazak M, Berkman CE (2008b) Cell-surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen. Prostate 68:955–964. https://doi.org/10.1002/pros.20753
Lütje S, Slavik R, Fendler W, Herrmann K, Eiber M (2017) PSMA ligands in prostate cancer—probe optimization and theranostic applications. Methods 130:42–50. https://doi.org/10.1016/j.ymeth.2017.06.026
Machulkin AE, Ivanenkov YA, Aladinskaya AV, Veselov MS, Aladinskiy VA, Beloglazkina EK, Koteliansky VE, Shakhbazyan AG, Sandulenko YB, Majouga AG (2016) Small-molecule PSMA ligands. Current state SAR and Perspectives. J Drug Target 24:679–693. https://doi.org/10.3109/1061186X.2016.1154564
Machulkin AE, Skvortsov DA, Ivanenkov YA, Ber AP, Kavalchuk MV, Aladinskaya AV, Uspenskaya AA, Shafikov RR, Plotnikova EA, Yakubovskaya RI, Nimenko EA, Zyk NU, Beloglazkina EK, Zyk NV, Koteliansky VE, Majouga AG (2019) Synthesis and biological evaluation of PSMA-targeting paclitaxel conjugates. Bioorg Med Chem Lett 29:2229–2235. https://doi.org/10.1016/j.bmcl.2019.06.035
Majer P, Jackson PF, Delahanty G, Grella BS, Ko Y-S, Li W, Liu Q, Maclin KM, Poláková J, Shaffer KA, Stoermer D, Vitharana D, Wang EY, Zakrzewski A, Rojas C, Slusher BS, Wozniak KM, Burak E, Limsakun T, Tsukamoto T (2003) Synthesis and biological evaluation of thiol-based inhibitors of glutamate carboxypeptidase II: discovery of an orally active GCP II inhibitor. J Med Chem 46:1989–1996. https://doi.org/10.1021/jm020515w
Maung J, Mallari JP, Girtsman TA, Wu LY, Rowley JA, Santiago NM, Brunelle AN, Berkman CE (2004) Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates. Bioorg Med Chem 12:4969–4979. https://doi.org/10.1016/j.bmc.2004.06.031
Mease RC, Foss CA, Pomper MG (2013) PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem 13:951–962. https://doi.org/10.2174/1568026611313080008
Mesters JR, Barinka C, Li W, Tsukamoto T, Majer P, Slusher BS, Konvalinka J, Hilgenfeld R (2006) Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. Embo j 25:1375–1384. https://doi.org/10.1038/sj.emboj.7600969
Mesters JR, Henning K, Hilgenfeld R (2007) Human glutamate carboxypeptidase II inhibition: structures of GCPII in complex with two potent inhibitors, quisqualate and 2-PMPA. Acta Crystallogr D Biol Crystallogr 63:508–513. https://doi.org/10.1107/S090744490700902X
Mlcochová P, Plechanovová A, Barinka C, Mahadevan D, Saldanha JW, Rulísek L, Konvalinka J (2007) Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesis. Febs J 274:4731–41. https://doi.org/10.1111/j.1742-4658.2007.06021.x
Mosayebnia M, Hajimahdi Z, Beiki D, Rezaeianpour M, Hajiramezanali M, Geramifar P, Sabzevari O, Amini M, Hatamabadi D, Shahhosseini S (2020) Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen. Bioorganic Chemistry 99:103743. https://doi.org/10.1016/j.bioorg.2020.103743
Mosayebnia M, Rezaeianpour S, Rikhtechi P, Hajimahdi Z, Beiki D, Kobarfard F, Sabzevari O, Amini M, Abdi K, Shahhosseini S (2018) Novel and efficient method for solid phase synthesis of urea-containing peptides targeting prostate specific membrane antigen (PSMA) in comparison with current methods. Iran J Pharm Res 17:917–926. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094430/. Accessed May 2018
Naushad SM, Janaki Ramaiah M, Stanley BA, Prasanna Lakshmi S, Vishnu Priya J, Hussain T, Alrokayan SA, Kutala VK (2016) In silico approaches to identify the potential inhibitors of glutamate carboxypeptidase II (GCPII) for neuroprotection. J Theor Biol 406:137–142. https://doi.org/10.1016/j.jtbi.2016.07.016
Navrátil M, Ptáček J, Šácha P, Starková J, Lubkowski J, Bařinka C, Konvalinka J (2014) Structural and biochemical characterization of the folyl-poly-γ-l-glutamate hydrolyzing activity of human glutamate carboxypeptidase II. Febs j 281:3228–42. https://doi.org/10.1111/febs.12857
Nedrow-Byers JR, Jabbes M, Jewett C, Ganguly T, He H, Liu T, Benny P, Bryan JN, Berkman CE (2012) A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent. Prostate 72:904–912. https://doi.org/10.1002/pros.21493
Nedrow-Byers JR, Moore AL, Ganguly T, Hopkins MR, Fulton MD, Benny PD, Berkman CE (2013) PSMA-targeted SPECT agents: mode of binding effect on in vitro performance. Prostate 73:355–362. https://doi.org/10.1002/pros.22575
Nikfarjam Z, Bavi O, Amini SK (2021) Potential effective inhibitory compounds against Prostate Specific Membrane Antigen (PSMA): a molecular docking and molecular dynamics study. Arch Biochem Biophys 699:108747. https://doi.org/10.1016/j.abb.2020.108747
Novakova Z, Cerny J, Choy CJ, Nedrow JR, Choi JK, Lubkowski J, Berkman CE, Barinka C (2016a) Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities. FEBS J 283:130–143. https://doi.org/10.1111/febs.13557
Novakova Z, Wozniak K, Jancarik A, Rais R, Wu Y, Pavlicek J, Ferraris D, Havlinova B, Ptacek J, Vavra J, Hin N, Rojas C, Majer P, Slusher BS, Tsukamoto T, Barinka C (2016b) Unprecedented binding mode of hydroxamate-based inhibitors of glutamate carboxypeptidase II: structural characterization and biological activity. J Med Chem 59:4539–4550. https://doi.org/10.1021/acs.jmedchem.5b01806
Pandit A, Sengupta S, Krishnan MA, Reddy RB, Sharma R, Venkatesh C (2018) First report on 3D-QSAR and molecular dynamics based docking studies of GCPII inhibitors for targeted drug delivery applications. J Mol Struct 1159:179–192. https://doi.org/10.1016/j.molstruc.2018.01.059
Pastorino S, Riondato M, Uccelli L, Giovacchini G, Giovannini E, Duce V, Ciarmiello A (2020) Toward the discovery and development of PSMA targeted inhibitors for nuclear medicine applications. Curr Radiopharm 13:63–79. https://doi.org/10.2174/1874471012666190729151540
Plechanovová A, Byun Y, Alquicer G, Škultetyová LU, Mlčochová P, Němcová A, Kim H-J, Navrátil M, Mease R, Lubkowski J, Pomper M, Konvalinka J, Rulíšek L, Bařinka C (2011) Novel substrate-based inhibitors of human glutamate carboxypeptidase II with enhanced lipophilicity. J Med Chem 54:7535–7546. https://doi.org/10.1021/jm200807m
Robinson MB, Blakely RD, Couto R, Coyle JT (1987) Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J Biol Chem 262:14498–14506. https://doi.org/10.1016/S0021-9258(18)47823-4
Rockey WM, Hernandez FJ, Huang SY, Cao S, Howell CA, Thomas GS, Liu XY, Lapteva N, Spencer DM, McNamara JO, Zou X, Chen SJ, Giangrande PH (2011) Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling. Nucleic Acid Ther 21:299–314. https://doi.org/10.1089/nat.2011.0313
Rowe SP, Gorin MA, Allaf ME, Pienta KJ, Tran PT, Pomper MG, Ross AE, Cho SY (2016) PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer Prostatic Dis 19:223–230. https://doi.org/10.1038/pcan.2016.13
Schäfer M, Bauder-Wust U, Leotta K, Zoller F, Mier W, Haberkorn U, Eisenhut M, Eder M (2012) A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer. EJNMMI Res 2:23. https://doi.org/10.1186/2191-219X-2-23
Sharma N, Baruah MM (2019) The microRNA signatures: aberrantly expressed miRNAs in prostate cancer. Clin Transl Oncol 21:126–144. https://doi.org/10.1007/s12094-018-1910-8
Søborg Pedersen K, Baun C, Michaelsen Nielsen K, Thisgaard H, Ingemann Jensen A, Zhuravlev F (2020) Design, synthesis, computational, and preclinical evaluation of (nat)Ti/(45)Ti-labeled urea-based glutamate PSMA ligand. Molecules 25. https://doi.org/10.3390/molecules25051104
Stoermer D, Liu Q, Hall MR, Flanary JM, Thomas AG, Rojas C, Slusher BS, Tsukamoto T (2003) Synthesis and biological evaluation of hydroxamate-based inhibitors of glutamate carboxypeptidase II. Bioorg Med Chem Lett 13:2097–2100. https://doi.org/10.1016/S0960-894X(03)00407-4
Su SL, Huang IP, Fair WR, Powell CT, Heston WD (1995) Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res 55:1441–1443. https://cancerres.aacrjournals.org/content/55/7/1441.short/. Accessed Apr 1995
Takatsu Y, Fujita Y, Tsukamoto T, Slusher BS, Hashimoto K (2011) Orally active glutamate carboxypeptidase II inhibitor 2-MPPA attenuates dizocilpine-induced prepulse inhibition deficits in mice. Brain Res 1371:82–86. https://doi.org/10.1016/j.brainres.2010.11.048
Tateishi U (2020) Prostate-specific membrane antigen (PSMA)-ligand positron emission tomography and radioligand therapy (RLT) of prostate cancer. Jpn J Clin Oncol 50:349–356. https://doi.org/10.1093/jjco/hyaa004
Tykvart J, Šácha P, Bařinka C, Knedlík T, Starková J, Lubkowski J, Konvalinka J (2012) Efficient and versatile one-step affinity purification of in vivo biotinylated proteins: expression, characterization and structure analysis of recombinant human glutamate carboxypeptidase II. Protein Expr Purif 82:106–115. https://doi.org/10.1016/j.pep.2011.11.016
Vahidfar N, Fallahpoor M, Farzanehfar S, Divband G, Ahmadzadehfar H (2019) Historical review of pharmacological development and dosimetry of PSMA-based theranostics for prostate cancer. J Radioanal Nucl Chem 322:237–248. https://doi.org/10.1007/s10967-019-06800-6
van der Post JP, de Visser SJ, de Kam ML, Woelfler M, Hilt DC, Vornov J, Burak ES, Bortey E, Slusher BS, Limsakun T, Cohen AF, van Gerven JM (2005) The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693. Br J Clin Pharmacol 60:128–136. https://doi.org/10.1111/j.1365-2125.2005.02396.x
Wang H, Byun Y, Barinka C, Pullambhatla M, Bhang H-EC, Fox JJ, Lubkowski J, Mease RC, Pomper MG (2010) Bioisosterism of urea-based GCPII inhibitors: synthesis and structure–activity relationship studies. Bioorg Med Chem Lett 20:392–397. https://doi.org/10.1016/j.bmcl.2009.10.061
Wirtz M, Schmidt A, Schottelius M, Robu S, Gunther T, Schwaiger M, Wester HJ (2018) Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity. EJNMMI Res 8:84. https://doi.org/10.1186/s13550-018-0440-2
Wright GL Jr, Haley C, Beckett ML, Schellhammer PF (1995) Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1:18–28. https://doi.org/10.1016/1078-1439(95)00002-Y
Wu LY, Anderson MO, Toriyabe Y, Maung J, Campbell TY, Tajon C, Kazak M, Moser J, Berkman CE (2007) The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen. Bioorg Med Chem 15:7434–7443. https://doi.org/10.1016/j.bmc.2007.07.028
Wu LY, Do JC, Kazak M, Page H, Toriyabe Y, Anderson MO, Berkman CE (2008) Phosphoramidate derivatives of hydroxysteroids as inhibitors of prostate-specific membrane antigen. Bioorg Med Chem Lett 18:281–284. https://doi.org/10.1016/j.bmcl.2007.10.096
Wustemann T, Bauder-Wust U, Schäfer M, Eder M, Benesova M, Leotta K, Kratochwil C, Haberkorn U, Kopka K, Mier W (2016) Design of internalizing PSMA-specific Glu-ureido-based radiotherapeuticals. Theranostics 6:1085–95. https://doi.org/10.7150/thno.13448
Yang X, Mease RC, Pullambhatla M, Lisok A, Chen Y, Foss CA, Wang Y, Shallal H, Edelman H, Hoye AT, Attardo G, Nimmagadda S, Pomper MG (2016) [18F]Fluorobenzoyllysinepentanedioic acid carbamates: new scaffolds for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA). J Med Chem 59:206–218. https://doi.org/10.1021/acs.jmedchem.5b01268
Zha Z, Ploessl K, Choi SR, Wu Z, Zhu L, Kung HF (2018) Synthesis and evaluation of a novel urea-based (68)Ga-complex for imaging PSMA binding in tumor. Nucl Med Biol 59:36–47. https://doi.org/10.1016/j.nucmedbio.2017.12.007
Zhang AX, Murelli RP, Barinka C, Michel J, Cocleaza A, Jorgensen WL, Lubkowski J, Spiegel DA (2010) A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules. J Am Chem Soc 132:12711–12716. https://doi.org/10.1021/ja104591m
Zhang W, Murakawa Y, Wozniak KM, Slusher B, Sima AA (2006) The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy. J Neurol Sci 247:217–223. https://doi.org/10.1016/j.jns.2006.05.052
Zhou J, Neale JH, Pomper MG, Kozikowski AP (2005) NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov 4:1015–1026. https://doi.org/10.1038/nrd1903
Author information
Authors and Affiliations
Contributions
ZN: literature search and data analysis, writing—original draft, visualization. FZ: literature search and data analysis. AN: supervision, editing. OB: conceptualization, supervision, writing—review and editing.
Corresponding author
Ethics declarations
Ethics approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Nikfarjam, Z., Zargari, F., Nowroozi, A. et al. Metamorphosis of prostate specific membrane antigen (PSMA) inhibitors. Biophys Rev 14, 303–315 (2022). https://doi.org/10.1007/s12551-021-00919-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12551-021-00919-1